ACCESSING CLASSIFIED FILES
Decrypting documents...
Your connection is being monitored
Back to Individuals
high risk
Stephen Ubl
President and CEO of PhRMA
Head of the pharmaceutical industry lobbying organization that spends over $350 million annually to block prescription drug price controls in the United States
Overview
Stephen J. Ubl (born circa 1970) has served as President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) since 2015, leading the most powerful and best-funded lobbying organization in American healthcare. Under his leadership, PhRMA has spent over $350 million annually on lobbying, campaign contributions, and advocacy to prevent Medicare from negotiating drug prices, block drug importation from Canada, and extend patent monopolies. PhRMA member companies include Pfizer, Johnson and Johnson, Merck, AbbVie, and virtually every major pharmaceutical manufacturer. Before joining PhRMA, Ubl served as president and CEO of the Advanced Medical Technology Association (AdvaMed), another powerful industry lobbying group representing medical device manufacturers. His career has been entirely dedicated to advancing the commercial interests of healthcare corporations in Washington, making him one of the most influential figures in maintaining the American pharmaceutical pricing system that charges Americans 2-3 times more than any other developed nation for the same medications.
Key Affiliations
Pharmaceutical Research and Manufacturers of America (PhRMA)
President and CEO (2015-present); leads $350M+ annual lobbying operation to block drug price controls
organization
Advanced Medical Technology Association (AdvaMed)
President and CEO (2005-2015); led medical device industry lobbying before moving to PhRMA
organization
Controversies & Concerns
Leads the pharmaceutical lobbying organization that spends over $350 million annually to block Medicare drug price negotiation, drug importation, and price transparency legislation
PhRMA under his leadership spent over $140 million in a single year opposing the Inflation Reduction Act provisions allowing Medicare to negotiate some drug prices
Member companies continued to raise drug prices 3-5 times the rate of inflation while PhRMA lobbied against price caps
Lobbied to extend patent monopolies and block generic competition through evergreening strategies that cost American patients billions
PhRMA funded front groups and astroturf campaigns to create the appearance of grassroots opposition to drug pricing reform
U.S. prescription drug prices remain 2-3 times higher than other developed nations in part due to PhRMA successful lobbying against price control legislation
Related Investigations (1)
Known Associates & Connections
Billy Tauzin
Former PhRMA president (2005-2010) and predecessor who established the revolving-door pattern from Congress to industry lobbying
Karen Ignagni
Former CEO of AHIP (health insurance lobby) who worked alongside PhRMA in opposing healthcare reform
Sources & Documentation
2 documented sources from official records, investigations, and reports
Personal Information
Education
- •Georgetown University (B.S.)
- •Georgetown University Law Center (J.D.)
Key Timeline
2005
Becomes President and CEO of AdvaMed, leading medical device industry lobbying
2015-11
Appointed President and CEO of PhRMA, the pharmaceutical industry primary lobbying arm
2019
Leads PhRMA opposition to bipartisan drug pricing bills; PhRMA spends record amounts on lobbying
2021
Directs PhRMA campaign against Build Back Better Act pharmaceutical pricing provisions
2022
PhRMA spends $140M+ opposing Inflation Reduction Act; Medicare negotiation provision passes despite lobbying
2023
Files lawsuit challenging constitutionality of Medicare drug price negotiation provisions of the IRA